Table 2D.
Characteristics of patients in the BF, 1W, and 4W cohort.
| Characteristic (n=16) | BF | 1W | 4W | Pa | Pb | |
|---|---|---|---|---|---|---|
| Gender (male/female) | 11/5 | |||||
| Age | 55.13 ± 8.25 | |||||
| Pathogeny (HBV/other) | 16/0 | |||||
| Liver cirrhosis (no/compensated/decompensated) | 2/9/5 | |||||
| Differentiation (well/moderate/poor/ND) | 1/2/3/10 | |||||
| BCLC stage (0/A/B) | 2/12/2 | |||||
| WBC (109/L) | 5.76 ± 2.12 | 7.13 ± 2.78 | 5.00 ± 2.21 | 0.146 | 0.253 | |
| HGB (g/L) | 145.79 ± 17.70 | 131.31 ± 14.96 | 143.69 ± 17.30 | 0.023 | 0.771 | |
| PLT (109/L) | 153.36 ± 58.85 | 177.31 ± 58.56 | 156 ± 67.43 | 0.299 | 0.884 | |
| ALT (U/L) | 29.17 ± 13.27 | 129.43 ± 114.29 | 29.13 ± 12.69 | 0.000 | 0.883 | |
| AST (U/L) | 28.33 ± 17.59 | 50.13 ± 26.65 | 28.53 ± 7.99 | 0.001 | 0.203 | |
| TBiL (μmmol/L) | 14.85 ± 4.30 | 13.98 ± 4.66 | 15.05 ± 4.22 | 0.516 | 0.961 | |
| ALB (g/L) | 41.61 ± 4.92 | 34.82 ± 3.92 | 41.88 ± 4.85 | 0.001 | 0.751 | |
| PT (s) | 11.77 ± 0.88 | 12.64 ± 1.32 | 11.94 ± 0.88 | 0.232 | 0.897 | |
| PTA (%) | 93.53 ± 11.61 | 83.67 ± 12.73 | 91.18 ± 9.69 | 0.179 | 0.897 | |
| AFP (ng/mL) | 469.88 ± 1361.61 | 146.87 ± 295.46 | 11.31 ± 24.27 | 0.738 | 0.097 | |
| PIVKA-II (mAU/mL) | 148 ± 164.35 | 76.42 ± 71.41 | 36.27 ± 21.16 | 0.44 | 0.019 | |
VI/M, vascular invasion/metastasis. HBV, hepatitis B virus. WBC, White Blood Cell. HGB, hemoglobin. PLT, platelet. ALT, alanine aminotransferase. AST, aspartate aminotransferase. TBil, total bilirubin. ALB, albumin. PT, prothrombin time. PTA, prothrombin activity. AFP, alpha-fetoprotein. PIVKA-II, protein induced by vitamin K absence or antagonist-II.
Data were expressed as mean ± SD. a: The data of the 1W group was compared with the BF group, P<0.05. b: The data of the 4W group was compared with the BF group, P<0.05.
Bold font indicates statistical significance of P values.